Products
Bezlotoxumab was approved in the United States and EU in 2016 and in many countries in 2017 as a concentrate for the preparation of an infusion solution (Zinplava).
Structure and properties
Bezlotoxumab (ATC J06BB21) is an IgG1 monoclonal antibody with a molecular weight of 148.2 kDa. It is produced by biotechnological methods.
Effects
Bezlotoxumab binds to toxin B (cytotoxin, TcdB) of and neutralizes its effects. Bezlotoxumab is not antibacterial and therefore is not suitable for therapy. The half-life is approximately 19 days.
Indications
To prevent recurrence of -infection in patients 18 years of age or older who are receiving antibiotic therapy for the disease and are at high risk for recurrence.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Drug-drug interactions are not known.
Adverse effects
The most common possible adverse effects include nausea, diarrhea, fever, and headache.
